Please assess the completion status of the following clinical trial:

Trial Title: Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in combination with Rituximab compared with Rituximab in combination with Placebo) and then relapsed or progressed with a TTP \>=6 months. Relapsed disease is defined as documented disease progression using the International Workshop Response Criteria (IWRC).~* Bidimensionally measurable disease with at least 1 lesion \>=2.0 cm in a single dimension.~* Acceptable hematologic, hepatic, and renal function.~Key Exclusion Criteria:~* Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this retreatment study.~* Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to Study Day 1.~* Transfusion-dependent subjects.~* Presence of central nervous system (CNS) lymphoma.~* Histologic transformation.~* Presence of pleural or peritoneal effusion with positive cytology for lymphoma.~* Another primary malignancy requiring active treatment.~* Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.~* New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).